{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/atrial-fibrillation/prescribing-information/diltiazem-verapamil/","result":{"pageContext":{"chapter":{"id":"d02a47f9-0498-503c-9cb1-0c3f89766d4f","slug":"diltiazem-verapamil","fullItemName":"Diltiazem and verapamil","depth":2,"htmlHeader":"<!-- begin field b1cf0187-9452-4b94-bd9b-21b21bff760d --><h2>Diltiazem and verapamil</h2><!-- end field b1cf0187-9452-4b94-bd9b-21b21bff760d -->","summary":"","htmlStringContent":"<!-- begin item 6767f48b-5102-4198-b280-bdfff3cb9cfb --><!-- end item 6767f48b-5102-4198-b280-bdfff3cb9cfb -->","topic":{"id":"c61747eb-a307-5da3-9878-9e952f2e1246","topicId":"e42fc175-7ae7-44c7-b7ef-b58a14733e7e","topicName":"Atrial fibrillation","slug":"atrial-fibrillation","lastRevised":"Last revised in October 2020","chapters":[{"id":"15747365-1cc2-550f-ad60-639db7df4ff0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ced6fef-0141-5375-b1c4-37d2756e7678","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75cb268e-28e7-51c1-87dd-0a86fbc0616b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1390db2e-6367-52cb-9af5-792d2e4d9310","slug":"changes","fullItemName":"Changes"},{"id":"f65a3e88-8f57-5c09-867a-ba88262e838c","slug":"update","fullItemName":"Update"}]},{"id":"16591b01-3ee5-5b14-a7e2-7a5226294933","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f3967a51-562c-5a5b-b55a-02dd39bfcbe9","slug":"goals","fullItemName":"Goals"},{"id":"5a66a5f8-9497-5664-abc1-d16cfe63bdd4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ca3b265-f279-56a1-94f0-c0e96dbeaaff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8bf96582-45d8-507c-9772-4c1092b4bd6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"992b55c8-2134-5283-b0f7-34608af53bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"677bafba-be09-57b3-a169-096ee3aa3fa1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6e491b1-6724-5c59-b127-fc29812ea52f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dab901c7-1cc0-5253-a4e0-e5b5bc04ba5e","slug":"definition","fullItemName":"Definition"},{"id":"39c5efdc-48cc-5b0a-85d7-f7da2de67a25","slug":"causes","fullItemName":"Causes"},{"id":"211e1811-bd20-5cfb-b7b9-c06c3fd223a3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"96a3b3f8-183a-52b6-9909-a81f0fd999dd","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"fc0c1acd-3cda-53a5-85ae-be117589c6bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a1e6d67-1c9c-5ea9-a30c-006e32e641c7","slug":"diagnosis-of-atrial-fibrillation","fullItemName":"Diagnosis of atrial fibrillation"}]},{"id":"42efe54e-8ff7-5283-ad5f-7dabdd2dcdff","fullItemName":"Management","slug":"management","subChapters":[{"id":"a955511a-8fbf-5bf9-aa82-b0e634a6325b","slug":"management-of-af","fullItemName":"Scenario: Management of AF"}]},{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2c20504-f7cb-54cc-adc0-c0cb70ec0ccb","slug":"beta-blockers-except-sotalol","fullItemName":"Beta-blockers (except sotalol)"},{"id":"d02a47f9-0498-503c-9cb1-0c3f89766d4f","slug":"diltiazem-verapamil","fullItemName":"Diltiazem and verapamil"},{"id":"037e75e8-454f-5dcd-a0b8-3e9ff5a5b309","slug":"digoxin","fullItemName":"Digoxin"},{"id":"c0c53c1d-4cd9-5e70-8a01-3d5f59d213cb","slug":"anticoagulants","fullItemName":"Anticoagulants"},{"id":"49e47ec1-0743-51db-a133-a2eed45d0eb0","slug":"aspirin-clopidogrel","fullItemName":"Aspirin and clopidogrel"},{"id":"5cb461d2-9502-5698-a467-30edd459c1b3","slug":"amiodarone-not-initiated-in-primary-care","fullItemName":"Amiodarone - not initiated in primary care"},{"id":"0fae1520-f160-57a2-af90-5b46bb20bdf5","slug":"sotalol-not-initiated-in-primary-care","fullItemName":"Sotalol - not initiated in primary care"}]},{"id":"1048ec97-41b1-5f93-a54d-1f58a8a56528","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5fff0dc2-1e01-590e-a159-76736c6a2ac0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b4497d2f-172b-54a5-99c6-5cd92c8469ba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d1d9c4e5-758a-5a99-93e3-4d2099a68d60","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0b86c2fd-54d8-569a-a8a8-ccadd53c17a0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e7ea1b2f-6198-53f7-b4f8-681296a03562","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3a114d83-bf8b-5507-b946-6af4f46c529e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5bbaf83e-cca2-55f4-a4c9-e6b808387a89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"35264766-cb08-593a-bf0d-18c298e68b2b","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 31bd6a4f-559e-4b7a-8156-d827d4a1289f --><h3>What dose of diltiazem or verapamil should I prescribe, and how should the dose be titrated?</h3><!-- end field 31bd6a4f-559e-4b7a-8156-d827d4a1289f -->","summary":"","htmlStringContent":"<!-- begin item bab90ea3-9e95-4eb1-b3db-1f9d4d46b545 --><!-- begin field 9b43021c-627f-4cf8-ac69-03a6a6624b80 --><ul><li><strong>Start with a low dose and titrate upwards until atrial fibrillation (AF) is controlled.</strong></li><li><strong>Diltiazem (off-label)</strong><ul><li>The usual starting dose (immediate release preparation) is 60 mg taken three times a day. Usual maintenance doses range from 60 mg to 120 mg taken three times a day.  These recommended doses are based on expert advice in the BMJ Best Practice guideline <em>Chronic Atrial Fibrillation </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">BMJ Best Practice, 2018a</a>] and are consistent with dose recommendations in the British National Formulary (BNF) for the treatment of angina [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>].</li><li>In elderly and patients with impaired hepatic or renal function<strong> </strong>the recommended starting dose is one tablet (60mg) twice daily. The heart rate should be measured regularly in these groups of patients and the dose should not be increased if the heart rate falls below 50 beats per minute [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017b</a>].</li><li>The 2014 AHA/ACC/HRS <em>Guideline for the Management of Patients With Atrial Fibrillation </em>states that an extended release (ER) formulation may also be used, with daily maintenance doses of 180 mg to 480 mg [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Fuster et al, 2011</a>]. This dose range is broadly consistent with those recommended in the BNF across different diltiazem ER preparations in the treatment of angina.  Different maintenance doses and dosing regimens are advised for the treatment of angina depending on the specific brand used [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>] and this should also be borne in mind when prescribing for the treatment of AF. When prescribing modified-release diltiazem, ensure that the required brand is specified each time [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>].</li></ul></li><li><strong>Verapamil</strong><ul><li>The usual starting dose (of an immediate release preparation) is 40 mg taken three times a day. The recommended maximum dose is 120 mg taken three times a day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>].</li></ul></li></ul><!-- end field 9b43021c-627f-4cf8-ac69-03a6a6624b80 --><!-- end item bab90ea3-9e95-4eb1-b3db-1f9d4d46b545 -->","subChapters":[]},{"id":"019bf6ba-524d-58d4-83d2-0a9b8faed6e0","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e635e7e3-d79c-4a43-aeec-81bda8511db2 --><h3>What are the contraindications and cautions of diltiazem and verapamil?</h3><!-- end field e635e7e3-d79c-4a43-aeec-81bda8511db2 -->","summary":"","htmlStringContent":"<!-- begin item af33d0d2-44fb-43f9-b591-23de1be88968 --><!-- begin field 4d908fcf-6d3d-4fb9-8391-054601afc5e1 --><ul><li><strong>Do not prescribe verapamil or diltiazem to </strong><strong>people with:</strong><ul><li>Left ventricular failure with pulmonary congestion.</li><li>Severe bradycardia (below 50 beats per minute for verapamil; below 40 beats per minute for diltiazem).</li><li>Second- or third-degree atrioventricular (AV) block, except in the presence of a functioning ventricular pacemaker — verapamil and diltiazem may induce complete AV block.</li><li>Severe hypotension (systolic blood pressure less than 90 mmHg).</li><li>Cardiogenic shock.</li><li>Severe aortic stenosis.</li><li>Congestive heart failure — they may further depress cardiac function and cause clinically significant deterioration.</li><li>Sick sinus syndrome, except in the presence of a functioning ventricular pacemaker.</li><li>People taking ivabradine. </li><li>Pregnant women or women of childbearing potential. The manufacturers advise that:<ul><li>Diltiazem should be avoided during pregnancy.</li><li>Verapamil should be avoided in the first trimester unless absolutely necessary, as it may reduce uterine blood flow with fetal hypoxia.</li></ul></li></ul></li><li><strong>In addition, do not prescribe verapamil to people with:</strong><ul><li>Wolff-Parkinson-White syndrome.</li><li>Acute myocardial infarction complicated by bradycardia, marked hypotension, or left ventricular failure.</li></ul></li><li><strong>Prescribe verapamil or diltiazem with caution to:</strong><ul><li>People at risk of developing an intestinal obstruction — calcium channel blockers have an inhibitory effect on intestinal motility.</li><li>People with renal or hepatic insufficiency, and elderly people — diltiazem and verapamil are metabolized in the liver; therefore, increased plasma concentrations of these drugs may be observed in these groups of people. Close monitoring, especially of heart rate, should be carried out at the beginning of treatment.</li><li>People with first degree AV block.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 4d908fcf-6d3d-4fb9-8391-054601afc5e1 --><!-- end item af33d0d2-44fb-43f9-b591-23de1be88968 -->","subChapters":[]},{"id":"9904eb64-de50-5d56-b952-63a75c09dbac","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c46109cc-4388-4d63-b2e3-a1bb380413cb --><h3>What are the common adverse effects associated with diltiazem and verapamil?</h3><!-- end field c46109cc-4388-4d63-b2e3-a1bb380413cb -->","summary":"","htmlStringContent":"<!-- begin item cdfa807a-6976-4199-82fe-ca5abf3ee700 --><!-- begin field 0a0392b6-0e0c-47ca-981c-97213dd0f2a7 --><ul><li><strong>Diltiazem commonly causes </strong>dizziness, atrioventricular block, palpitations, gastrointestinal disorders (for example constipation, nausea, and dyspepsia), erythema, malaise, and fatigue.<ul><li>Sinus arrest, or cardiac arrest (asystole) may also occur (unknown frequency).</li></ul></li><li><strong>Verapamil commonly causes constipation, </strong>which may be improved by eating more fibre and drinking plenty of fluids. Less commonly, nausea, vomiting, dizziness, and fatigue have also been reported.</li><li><strong>Bradycardia </strong>can result from taking diltiazem or verapamil.</li><li><strong>Vasodilatory adverse effects </strong>(such as flushing, headaches, and ankle swelling) are less common with rate-limiting calcium-channel blockers than with dihydropyridine calcium-channel blockers and often improve with continued use. Do not routinely prescribe diuretics to relieve ankle swelling. However, they may help if there is marked oedema.</li><li><strong>Acute renal failure secondary to decreased renal perfusion</strong> has been reported in patients taking diltiazem who have reduced left ventricular function, severe bradycardia, or severe hypotension.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2020a</a>]</p><!-- end field 0a0392b6-0e0c-47ca-981c-97213dd0f2a7 --><!-- end item cdfa807a-6976-4199-82fe-ca5abf3ee700 -->","subChapters":[]},{"id":"ea9f70fe-4540-5b3d-ae4b-a0328835f823","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 36d9f408-7a73-4448-b872-354349c403f0 --><h3>What are the key drug interactions with verapamil and diltiazem?</h3><!-- end field 36d9f408-7a73-4448-b872-354349c403f0 -->","summary":"","htmlStringContent":"<!-- begin item a35d74f1-1fc3-46cf-9a0e-656e3bc5da16 --><!-- begin field a635efa9-294c-42bc-9f98-923ee3011894 --><p><strong>Key drug interactions with verapamil and diltiazem include:</strong></p><ul><li><strong>Alpha-blockers, ACE-inhibitors, angiotensin-II receptor antagonists, antipsychotics, anxiolytics and hypnotics, baclofen, clonidine, co-beneldopa, co-careldopa, diazoxide, diuretics, hydralazine, levodopa, MAOIs, methyldopa, minoxidil, moxisylyte, moxonidine, nitrates,</strong> <strong>sodium nitroprusside, and tizanidine </strong>— enhanced antihypertensive effect.</li><li><strong>Amiodarone </strong>—<strong> </strong>increased risk of bradycardia, AV block and myocardial depression when given with diltiazem or verapamil.</li><li><strong>Aminophylline and theophylline</strong> — plasma concentrations increased by concurrent use of calcium channel blockers.</li><li><strong>Antidepressants</strong> — tricyclic antidepressants, mirtazapine, and trazodone should be prescribed with caution in people taking calcium-channel blockers, as there is an increased risk of postural hypotension.</li><li><strong>Atazanavir</strong> — plasma concentration of diltiazem increased with concurrent use (reduce dose of diltiazem).</li><li><strong>Avanafil, Bosutinib, ciclosporin</strong> — concurrent use with diltiazem or verapamil may lead to increased plasma concentrations of these drugs. Dose alterations may be required.</li><li><strong>Carbamazepine</strong> — concurrent use with diltiazem or verapamil may lead to enhanced effects of carbamazepine. Dose alterations may be required.</li><li><strong>Colchicine</strong> — diltiazem and verapamil possibly increase risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment).</li><li><strong>Beta-blockers </strong>— verapamil contraindicated (risk of reduced cardiac output and heart failure); diltiazem with caution (diltiazem has a smaller negative inotropic effect than verapamil – monitor the person's pulse and blood pressure carefully due to the risk of bradycardia); hypotensive effect enhanced with all calcium channel blockers.</li><li><strong>Clarithromycin, erythromycin</strong> — metabolism of calcium-channel blockers possibly inhibited leading to increased risk of side-effects.</li><li><strong>Dabigatran and lenalidomide </strong>— verapamil possibly increases plasma concentrations of these drugs.</li><li><strong>Digoxin</strong> — concurrent use with diltiazem or verapamil may lead to increased plasma concentrations of digoxin. Monitor for signs of toxicity and consider monitoring plasma digoxin levels.</li><li><strong>Disopyramide</strong> — concurrent use with verapamil may lead to increased risk of myocardial depression and asystole.</li><li><strong>Dronedarone, flecainide</strong> — increased risk of bradycardia and myocardial depression when diltiazem or verapamil given with these drugs.</li><li><strong>Enzyme-inducing drugs</strong> (such as carbamazepine) — increase the elimination of dihydropyridines, resulting in a reduced hypotensive effect. Monitor the clinical response to the dihydropyridine and increase its dose if necessary. Consider reducing the dihydropyridine dose if the enzyme-inducing drug is discontinued.</li><li><strong>mTOR inhibitors (sirolimus, temsirolimus, everolimus)</strong> — verapamil is a CYP3A inhibitors, concomitant use with these drugs may increase their levels.</li><li><strong>Fingolimod</strong> — possible increased risk of bradycardia when diltiazem or verapamil is given with fingolimod.</li><li><strong>Fosphenytoin</strong> — diltiazem increases plasma concentration of fosphenytoin but also effect of diltiazem reduced.</li><li><strong>Ibrutinib, ivabradine, lomitapide, lurasidone, olaparib, sirolimus and tacrolimus</strong> — diltiazem and verapamil possibly increase the plasma concentrations of these drugs. Reduce dose of ibrutinib, avoid concomitant use with ivabradine, lomitapide, and olaparib.</li><li><strong>Mefloquine</strong> — possible increased risk of bradycardia during concurrent use with calcium channel blockers.</li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — hypotensive effect of calcium channel blockers antagonised.</li><li><strong>Phenobarbital, primidone</strong> — effects of calcium-channel blockers probably reduced with concurrent use. </li><li><strong>Phenytoin</strong> — diltiazem increases plasma concentration of phenytoin, effect of diltiazem also reduced.</li><li><strong>Rifampicin</strong> — plasma concentration of diltiazem and verapamil decreased with concurrent use.</li><li><strong>Ritonavir</strong> — plasma concentration of calcium-channel blockers possibly increased with concurrent use.</li><li><strong>Sirolimus</strong> — plasma concentration of both drugs increased when verapamil is given with sirolimus.</li><li><strong>Statins</strong> — possible increased risk of myopathy when diltiazem or verapamil given with simvastatin, plasma concentration of verapamil increased by atorvastatin, also possible increased risk of myopathy (consider reducing dose of atorvastatin).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field a635efa9-294c-42bc-9f98-923ee3011894 --><!-- end item a35d74f1-1fc3-46cf-9a0e-656e3bc5da16 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}